NEW PUBLICATION: Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients

The clinical effectiveness of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in immunosuppressed solid organ and islet transplant (SOT) recipients is unclear.

Chris J. Callaghan; Lisa Mumford; Rebecca M.K. Curtis; Sarah V. Williams; Heather Whitaker; Nick Andrews; Jamie Lopez Bernal; Ines Ushiro-Lumb; Gavin J. Pettigrew; Douglas Thorburn; R. Forsythe; Romme Ravanan on behalf of the NHSBT Organ and Tissue Donation and Transplantation Clinical Team


On August 31, 2021, it was found that 3080 (7.1%) were unvaccinated, 1141 (2.6%) had 1 vaccine dose, and 39 260 (90.3%) had 2 vaccine doses. There were 4147 SARS-CoV-2 infections and 407 deaths (unadjusted case fatality rate 9.8%). The risk-adjusted infection incidence rate ratio was 1.29 (1.03-1.61), implying that vaccination was not associated with reduction in risk of testing positive for SARS-CoV-2 RNA. Overall, the hazard ratio for death within 28 d of SARS-CoV-2 infection was 0.80 (0.63-1.00), a 20% reduction in risk of death in vaccinated patients (P = 0.05). Two doses of ChAdOx1-S were associated with a significantly reduced risk of death (hazard ratio, 0.69; 0.52-0.92), whereas vaccination with BNT162b2 was not (0.97; 0.71-1.31).


Read the full publication here:


Transplantation: January 04, 2022 – Volume – Issue – doi: 10.1097/TP.0000000000004059